Qin Shukui, Liu Tianshu, Xu Jianming, Li Qi, Cheng Ying, Zhang Aimar, Esser Regina, Chang Helena, Li Jin
Cancer Center of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, 210002, China.
Department of Oncology, Zhongshan Hospital of Fudan University, Shanghai, 200032, China.
Future Oncol. 2023 May;19(15):1053-1061. doi: 10.2217/fon-2022-1068. Epub 2023 Apr 5.
To examine the impact of tumor sidedness on clinical outcomes in Chinese patients with metastatic colorectal cancer treated with folinic acid/fluorouracil/oxaliplatin (FOLFOX-4) ± cetuximab in the TAILOR trial. Clinical data from 391 patients were evaluated for tumor sidedness. Patients with left-sided tumors who received cetuximab plus FOLFOX-4 had a significantly longer overall survival (medians: 22.0 vs 18.3 months; p = 0.007) and progression-free survival (medians: 9.3 vs 7.9 months; p = 0.006) compared with FOLFOX-4 alone. Overall survival (medians: 11.5 vs 9.4 months; p = 0.664) and progression-free survival (medians: 7.4 vs 4.5 months; p = 0.068) also improved in patients with right-sided tumors. Adding cetuximab to first-line FOLFOX-4 in patients with metastatic colorectal cancer improved clinical outcomes irrespective of primary tumor side.
在TAILOR试验中，研究肿瘤部位对接受亚叶酸钙/氟尿嘧啶/奥沙利铂（FOLFOX-4）±西妥昔单抗治疗的中国转移性结直肠癌患者临床结局的影响。对391例患者的临床数据进行肿瘤部位评估。与单纯接受FOLFOX-4治疗相比，接受西妥昔单抗联合FOLFOX-4治疗的左侧肿瘤患者总生存期（中位数：22.0个月对18.3个月；p = 0.007）和无进展生存期（中位数：9.3个月对7.9个月；p = 0.006）显著更长。右侧肿瘤患者的总生存期（中位数：11.5个月对9.4个月；p = 0.664）和无进展生存期（中位数：7.4个月对4.5个月；p = 0.068）也有所改善。在转移性结直肠癌患者的一线FOLFOX-4治疗中添加西妥昔单抗可改善临床结局，无论原发肿瘤部位如何。
